ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO953

Using Machine Learning to Predict Optimal Renal Replacement Therapy Starts in Patients with Advanced Renal Function Loss

Session Information

Category: Dialysis

  • 704 Dialysis: Vascular Access

Authors

  • Fielding, Ollie, pulseData, New York, New York, United States
  • Kipers, Chris, pulseData, New York, New York, United States
  • Son, Jung Hoon, pulseData, New York, New York, United States
  • Lee, Edward, pulseData, New York, New York, United States
  • Levine, Daniel, The Rogosin Institute, New York, New York, United States
  • Parker, Thomas, The Rogosin Institute, New York, New York, United States
  • Smith, Barry H., The Rogosin Institute, New York, New York, United States
  • Silberzweig, Jeffrey I., The Rogosin Institute, New York, New York, United States
Background

Building on our previous work using machine learning techniques to identify patients at risk of progression to End Stage Renal Disease (ESRD), we focused this model more precisely on identifying patients with advanced kidney function loss who should plan for optimal renal replacement therapy. The most recent USRDS data indicates that more than 80% of patients begin hemodialysis with a catheter and only 2.5% receive preemptive renal transplants.

Methods

Using longitudinal patient data of 109,028 patients from The Rogosin Institute, we identified a cohort of patients with advanced kidney function loss, defined as an eGFR <20, and built a machine learning model to predict which patients would need to begin renal replacement therapy in the next six months, based on progression to an eGFR <10. Information in the model included patient demographics, vital signs, comorbidities, laboratory values, and medications. We used an algorithm to remove measurements taken during an AKI episode. We evaluated whether the model could identify the need for renal replacement therapy prior to clinical need.

Results

Between 2014 and 2016, only 17 of 214 patients who progressed within a six month period received an AV fistula prior to their decline to an eGFR <10. The model identified 181 patients as the top quintile of risk who would benefit from preparation for renal replacement therapy. Our model has an AUC of 0.93, a sensitivity of 0.81 and a specificity of 0.89 at the top quintile.

Conclusion

We demonstrate improved ability to identify patients who will need renal replacement therapy using an advanced machine learning model incorporating longitudinal data commonly available in EHRs. We plan to augment clinical decision making with machine learning tools.

Numbers for 2014-2016
Total patient cohort109,028
Patients in dataset who progress to an eGFR <202,416
Patients who continue on to an eGFR <10241
Patients who received an AV fistula in the six months prior to their decline to an eGFR <1017
Patients identified by the model (at the top risk quintile) in the six months prior to a decline to an eGFR <10181

Funding

  • Commercial Support – pulseData